Micregen, the UK-based biotechnology company pioneering stem cell secretome technology, has presented new preclinical research findings at the 4th Edition Global Longevity Federation Conference, where the company served as an Official Conference Partner.
Development Director Dr. Robert Mitchell took to the virtual stage to present findings from Micregen’s newly submitted research paper on Secretomix® – the company’s proprietary stem cell secretome platform – exploring its potential to slow the progression of Alzheimer’s disease and Motor Neurone Disease (MND/ALS).
What the Research Found
The findings represent a significant step forward in the search for effective treatments for two of the world’s most devastating neurological conditions.
In preclinical models of Alzheimer’s disease, Secretomix® formulations demonstrated measurable preservation of memory function, alongside a reduction in neuroinflammation – widely recognised as one of the key drivers of cognitive decline.
In Motor Neurone Disease models, Secretomix® significantly slowed the decline in movement and coordination, again without disturbing the underlying disease pathology. Human blood analysis further confirmed broad anti-inflammatory effects, strengthening the platform’s real-world translational potential.
A Cell-Free Approach to Neurodegeneration
Unlike traditional stem cell therapies, Secretomix® is a cell-free, non-invasive platform that harnesses the powerful signalling molecules naturally secreted by stem cells. This approach offers a safer and more scalable pathway to treatment – with the potential to intervene early, before irreversible neurological damage occurs.
Dr. Robert Mitchell, Development Director at Micregen, commented:
“These findings are an important milestone for Micregen and for the wider field of neurodegeneration research. The ability to reduce neuroinflammation and preserve function in two such different conditions speaks to the broad potential of the Secretomix® platform. We look forward to sharing more as this research progresses.”
What’s Next
Micregen’s research paper has been formally submitted for peer review. The company will continue to advance the Secretomix® platform and share updates as the science develops.
The full white paper is available to download below.
About Micregen
Micregen is a UK biotechnology company developing stem cell secretome technologies for the treatment of neurological and age-related conditions. Its proprietary Secretomix® platform is at the forefront of cell-free therapeutic research.
For media enquiries contact: info@micregen.com www.micregen.com